An observational study in Type 2 Diabetes Mellitus, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Handok Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 2 by Handok Inc. — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Handok Inc..
Among the 15 studies in Diabetes Mellitus, Type 2 by Handok Inc., this one is the only one that started in 2016, is the only observational one, and was the 12th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 15 studies in Diabetes Mellitus, Type 2 by Handok Inc. is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,983 is above the median of 300 across 1,744 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 178 across the 14 interventional studies, 2,983 across the 1 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Diabetes Mellitus, Type 2 by Handok Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed as a prospective, observational, multi-centre study to evaluate the efficacy and safety of Teneligliptin when switched from other DPP-4 inhibitors in type 2 DM with inadequate glycemic control
Type 2 DM patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in HbA1c
To assess change from baseline in glycated hemoglobin (HbA1c)
Time frame: at 12 weeks after switching to Teneligliptin
Change in HbA1c
To assess change from baseline in HbA1c
Time frame: at 24, 52 weeks after switching to Teneligliptin
Change in FBG
To assess change from baseline in fasting blood glucose (FBG)
Time frame: at 12, 24, 52 weeks after switching to Teneligliptin
Change in body weight, BMI
To assess change from baseline in body weight and body mass index (BMI)
Time frame: at 12, 24, 52 weeks after switching to Teneligliptin
Change in lipid profile(Total cholesterol, LDL cholesterol, HDL cholesterol)
To assess change from baseline in serum lipid profile (total cholesterol, LDL and HDL cholesterol, triglyceride)
Time frame: at 12, 24, 52 weeks after switching to Teneligliptin
The percentage of patients with HbA1c <7.0% and <6.5%
To assess the percentage of patients with HbA1c \<7.0% and \<6.5%
Time frame: at Weeks 12, 24, and 52 of teneligliptin treatment
The percentage of patients with a decrease from baseline in HbA1c
To assess the percentage of patients with a decrease from baseline in HbA1c by ≥0.3% and ≥ 0.5%
Time frame: at Weeks 12, 24, and 52 of teneligliptin treatment
Safety Outcome
To assess the safety of teneligliptin treatment(AE, ADR, SAE etc.)
Time frame: at Weeks 12, 24, and 52 of teneligliptin treatment
Plan to share: No
Ran from Jan 2016 to primary completion in Sep 2019, 44 months.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's 44 months is above that.
Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.